Advanced search
Publication Cover
International Journal of Nanomedicine Volume 18, 2023 - Issue
Submit an article Journal homepage
407
Views
3
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Fabrication and Evaluation of a pH-Responsive Nanocomposite-Based Colonic Delivery System for Improving the Oral Efficacy of Liraglutide

Jae Geun SongBK21 FOUR Team and Integrated Research Institute for Drug Development, College of Pharmacy, Dongguk University-Seoul, Goyang, 10326, KoreaView further author information
,
Da Hyun KimBK21 FOUR Team and Integrated Research Institute for Drug Development, College of Pharmacy, Dongguk University-Seoul, Goyang, 10326, KoreaView further author information
&
Hyo-Kyung HanBK21 FOUR Team and Integrated Research Institute for Drug Development, College of Pharmacy, Dongguk University-Seoul, Goyang, 10326, KoreaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-9556-7920View further author information
ORCID Icon
Pages 3937-3949 | Received 20 Apr 2023, Accepted 29 Jun 2023, Published online: 19 Jul 2023

References

  • Lagassé HD, Alexaki A, Simhadri VL, et al. Recent advances in (therapeutic protein) drug development. F1000Research. 2017;6:113.
  • Bajracharya R, Song JG, Back SY, Han H-K. Recent advancements in non-invasive formulations for protein drug delivery. Comput Struct Biotechnol J. 2019;17:1290–1308.
  • Caughey GE, Vitry AI, Gilbert AL, Roughead EE. Prevalence of comorbidity of chronic diseases in Australia. BMC Public Health. 2008;8:1–13.
  • Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.
  • Jacobsen LV, Flint A, Olsen AK, Ingwersen SH. Liraglutide in type 2 diabetes mellitus: clinical pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2016;55:657–672.
  • Vilsbøll T. Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs. 2007;16(2):231–237.
  • Wajcberg E, Amarah A. Liraglutide in the management of type 2 diabetes. Drug Des Devel Ther. 2010;279–290.
  • Sharma AN, Ligade SS, Sharma JN, Shukla P, Elased KM, Lucot JB. GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats. Metab Brain Dis. 2015;30:519–527.
  • Lin C-H, Shao L, Zhang Y-M, et al. An evaluation of liraglutide including its efficacy and safety for the treatment of obesity. Expert Opin Pharmacother. 2020;21(3):275–285.
  • Drucker DJ. Advances in oral peptide therapeutics. Nat Rev Drug Discov. 2020;19(4):277–289.
  • Ismail R, Csoka I. Novel strategies in the oral delivery of antidiabetic peptide drugs–Insulin, GLP 1 and its analogs. Eur J Pharm Biopharm. 2017;115:257–267.
  • Patil AJ, Mann S. Self-assembly of bio–inorganic nanohybrids using organoclay building blocks. J Mater Chem. 2008;18(39):4605–4615.
  • Lee SH, Back S-Y, Song JG, Han H-K. Enhanced oral delivery of insulin via the colon-targeted nanocomposite system of organoclay/glycol chitosan/Eudragit® S100. J Nanobiotechnology. 2020;18(1):1–10.
  • Lee SH, Song JG, Han H-K. Development of pH-responsive organic-inorganic hybrid nanocomposites as an effective oral delivery system of protein drugs. J Control Release. 2019;311:74–84.
  • Song JG, Lee SH, Han H-K. Biophysical evaluation of aminoclay as an effective protectant for protein stabilization during freeze-drying and storage. Int J Nanomed. 2016;11:6609.
  • Xiao B, Si X, Zhang M, Merlin D. Oral administration of pH-sensitive curcumin-loaded microparticles for ulcerative colitis therapy. Colloids Surf B. 2015;135:379–385.
  • Furman BL. Streptozotocin‐induced diabetic models in mice and rats. Curr Protoc Pharmacol. 2015;70(1):5.47. 1–5.47. 20.
  • Senduran N, Yadav HN, Vishwakarma VK, et al. Orally deliverable nanoformulation of liraglutide against type 2 diabetic rat model. J Drug Deliv Sci Technol. 2020;56:101513.
  • Presas E, Tovar S, Cuñarro J, O’Shea JP, O’Driscoll CM. Pre-clinical evaluation of a modified cyclodextrin-based nanoparticle for intestinal delivery of liraglutide. J Pharm Sci. 2021;110(1):292–300.
  • Song JG, Lee SH, Han H-K. Development of an M cell targeted nanocomposite system for effective oral protein delivery: preparation, in vitro and in vivo characterization. J Nanobiotechnology. 2021;19:1–11.
  • M-G L, W-L L, Wang J-C, et al. Preparation and characterization of insulin nanoparticles employing chitosan and poly (methylmethacrylate/methylmethacrylic acid) copolymer. J Nanosci Nanotechnol. 2006;6(9–10):2874–2886.
  • Zhao M, Lee SH, Song JG, Kim HY, Han H-K. Enhanced oral absorption of sorafenib via the layer-by-layer deposition of a pH-sensitive polymer and glycol chitosan on the liposome. Int J Pharm. 2018;544(1):14–20.
  • Dubey SK, Parab S, Dabholkar N, et al. Oral peptide delivery: challenges and the way ahead. Drug Discov Today Technol. 2021;26(4):931–950.
  • Peppas NA, Kavimandan NJ. Nanoscale analysis of protein and peptide absorption: insulin absorption using complexation and pH-sensitive hydrogels as delivery vehicles. Eur J Pharm Sci. 2006;29(3–4):183–197.
  • Kim S-Y, Kwon W-A, Shin S-P, et al. Electrostatic interaction of tumor-targeting adenoviruses with aminoclay acquires enhanced infectivity to tumor cells inside the bladder and has better cytotoxic activity. Drug Deliv. 2018;25(1):49–58.
  • Azevedo C, Macedo MH, Sarmento B. Strategies for the enhanced intracellular delivery of nanomaterials. Drug Discov Today. 2018;23(5):944–959.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.